Currently, Dr.Chen divides his time between patient care and clinical research with a focus on patients undergoing bone marrow/stem cell transplantation. He invites you to contact him directly with any questions. New patients please call 617-724-6587
- Centers & Specialties
- Clinical Interests
- Bone marrow, Stem cell, Cord blood transplant
- Acute and chronic leukemia
- Hodgkin's and Non-Hodgkin's lymphoma
- Multiple myeloma
- Aplastic anemia
- Myelodysplastic syndrome (MDS)
- Medical Education
- MD, Harvard Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Dana Farber Cancer Institute
- Board Certifications
- Medical Oncology
- Boston: Massachusetts General Hospital
- Patient Gateway
- Yes, learn more
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
Yi-Bin Chen grew up in New Jersey. He majored in molecular biology, earning a B.S./M.S. at Yale University before attending medical school at Harvard Medical School. Subsequently, he did his internship and residency at Massachusetts General Hospital including an additional year as Chief Resident. This was followed by a fellowship in hematology / oncology at the Dana-Farber Partners combined program. In 2008, he joined the staff of the Bone Marrow Transplant Unit at the MGH Cancer Center. His interests mainly revolve around clinical care of patients underoing autologous and allogeneic stem cell transplant. In addition, he serves as Director oc Clinical Research for the BMT program at MGH, directing an active portfolio of clinical trials aimed to improve outcomes for patients undergoing stem cell transplantation. He collaborates extensively with local and national colleagues as well as industry in addition to developing his own original clinical trials. He currently lives in Needham, MA with his wife and 2 children.
- Research Summary
- Dr. Chen is the Director of Clinical Research for the BMT program at MGH. His research interests mainy revolve around improving the outcomes for patients undergoing autologous and allogeneic stem cell transplantation. He serves as institution and overall principal investigator for many clinical trials. MGH is an active participant in several national collaborative group trials, specifically from Alliance and the BMT CTN. In addition, Dr. Chen currently has several of his own investigator-initiated clinical trials open with multiple others in development. These include:
1. Use of brentuximab vedotin to target CD30 in the treatment of acute graft-vs-host disease (GVHD)
2. Use of brentuximab vedotin to target CD30 in the treatment of chronic GVHD
3. Use of the novel drug LDE225 in the treatment of chronic GVHD
4. Inhibition of the FLT3 mutation after allogeneic transplant for patients with FLT3-ITD mutated AML
5. Combined bone marrow and kidney transplantation using partially matched family donors
Dr. Chen invites you to contact him directly to inquire about the latest clinical investigations available at MGH.
Chen YB, Li S, Lane AA, et al. ?Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD AML.? Biol Blood Marrow Transplant. 2014, 20(12):2042-8.
Chen, YB, McDonough S, Hasserjian R, et al. "Expression of CD30 in Patients with Acute Graft-vs.-Host Disease." Blood 2012; 120(3):691-6.
Chen YB, Kim H, McDonough S, et al."Upregulation of a4b7 integrin on peripheral blood memory T-cells predicts for intestinal graft-versus-host disease (GVHD) following allogeneic stem cell transplantation." Biol of Blood and Marrow Transplant. 2009;15:1066-76.
Chen YB and Spitzer TR. "Current status of reduced intensity transplantation using alternative donors." Leukemia. 2008;22:31-41.
55 Fruit St
Boston MA, 02114-2696
Phone 1: 617-726-5765
Phone 2: 617-724-1124